leadf
logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics raises $1.8 million in well supported share placement

Proceeds from the SPP and recent placement will be used to progress the paxalisib clinical trial program and to complete analysis of the ongoing Phase I study of Cantrixil.

Kazia Therapeutics Ltd - Kazia Therapeutics raises $1.8 million in SPP to shareholders
Shares under the SPP were offered at a price of 40 cents per share

Kazia Therapeutics Ltd (ASX:KZA) has raised $1.8 million through a share purchase plan (SPP) to eligible shareholders in Australia and New Zealand and this follows a $7.2 million institutional placement.

The SPP offered shareholders the opportunity to apply for up to $30,000 worth of shares in Kazia, without incurring brokerage or other transaction costs.

Shares were offered at a price of 40 cents per share, which was equal to the price under the institutional placement announced on April 8 which raised approximately $7.2 million.

Funds from the placements will be used to progress the paxalisib clinical trial program and to complete analysis of the ongoing Phase I study of Cantrixil, to continue to provide contributory funding towards four other trials and as working capital for the company.

Proceeds to “enrich” R&D programs

Chairman Iain Ross said: “Following our successful institutional placement in early April, the board considered it imperative that existing shareholders have the opportunity to augment their holdings in the company at the same price as the institutional investors.

“We are delighted to have received a very high level of engagement with this SPP.

“As on previous occasions, the proceeds will be applied directly to progressing and enriching the company’s R&D programs.

“We expect paxalisib to transition to a pivotal study in the second half of this year, so it is a particularly critical time for the company.

“We are, as always, grateful for the strong and enthusiastic support of our shareholders and look forward to sharing further progress as the year advances.”

4.5 million new shares to be issued

Around 4.5 million new shares will be issued under the SPP and it is expected that new shares under the SPP will be issued by Kazia and allotted to successful applicants on Monday, May 11.

Normal trading of SPP shares is expected to begin on Tuesday, May 12, with holding statements to be dispatched around Thursday, May 14.

Quick facts: Kazia Therapeutics Ltd

Price: 0.93 AUD

ASX:KZA
Market: ASX
Market Cap: $67.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 08/21/2020

2 min read